Voices Against Brain Cancer (VABC), a nonprofit organization dedicated to finding a cure for brain cancer, has awarded Tocagen, a privately held biopharmaceutical, a grant to support the clinical investigation of Toca 511 & Toca FC in patients diagnosed with a recurrent high grade glioma brain cancer (Grade 3 or Grade 4). 

"Toca 511 & Toca FC is a promising new approach in clinical trials that has the potential to help patients with brain cancer, and we are excited to provide support for this program," said Mario Lichtenstein, co-founder of VABC. 

Tocagen is enrolling patients in phase I clinical trials at sites across the U.S.